Catalyst
Slingshot members are tracking this event:
Vertex (VRTX) Initiates Phase 2 Study Evaluating VX-440/Tezacaftor/Kalydeco in ~40 CF Patients With F508del Mutation and One Minimal Function Mutation and ~25 CF patients With Two Copies of the F508del Mutation
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VRTX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 25, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Trial Initiation, Vx-440, Tezacaftor, Kalydeco, F508del Mutation, Minimal Function Mutation
